Huisheng Pharmaceutical vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Huisheng Pharmaceutical is a Chinese pharma company specializing in traditional Chinese medicine and modern drug formulations; operates across R&D, manufacturing, and distribution; serves domestic and international markets from its base in China.
About
Huisheng Pharmaceutical is a Chinese pharmaceutical company engaged in the research, development, production, and distribution of both traditional Chinese medicine (TCM) and modern pharmaceutical products. Founded and headquartered in China, the company operates across the full pharmaceutical value chain — from drug discovery and formulation development through to large-scale manufacturing and commercial distribution. Its product portfolio spans proprietary TCM preparations, prescription pharmaceuticals, and health supplements targeting a range of therapeutic areas including cardiovascular, respiratory, and metabolic conditions.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Huisheng Pharmaceutical vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.